Loading…
← CockpitCompetitor Analysis › 4503.T Astellas PharmaOpen in the cockpit ↗

Astellas Pharma4503.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese pharma selling drugs for prostate cancer (Xtandi), urology, transplant and ophthalmology.

Momentum leader 91
Mkt cap
$31.4B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$103M
20-day average traded
Fwd P/E
12.9×
forward earnings
ROIC−WACC
+12.4 pp
WACC 5.4%
Hurdle
-20 pp
Req g minus delivered
Next earnings
82 days
8 Feb 2027
Close · JPY¥2,725
1D-0.2%
1W+3.4%
1M+12.4%
3M+15.6%
6M+17.2%
YTD+32.2%
1Y+62.4%
ATR %2.8%
52w lowhigh1.6% off high

What Astellas Pharma does

Japanese pharma selling drugs for prostate cancer (Xtandi), urology, transplant and ophthalmology.

Sells branded prescription drugs through its own sales teams in Japan, Europe and elsewhere, while in the US it shares Xtandi and Padcev profit with Pfizer. Xtandi has long carried the company and faces patent expiry later this decade, so newer launches such as Veozah (menopausal hot flashes) and Izervay (an eye disease) matter.

Products and services

  • Xtandi (prostate cancer)
  • Padcev (bladder cancer ADC)
  • Transplant immunosuppressants
  • Ophthalmology (gene therapy)

Customers

  • Oncologists, urologists, transplant centers worldw

Where it sits in the supply chain

  • Healthcare
  • Pharmaceuticals
  • Global branded drug development & sales

What could go right

  • Padcev label expansion
  • New pipeline launches offsetting Xtandi decline

What could go wrong

  • Xtandi patent expiry
  • Pipeline execution risk

Moat: narrow (IP / patents, distribution). Global partnership drugs (Xtandi with Pfizer, Padcev with Seagen) but facing upcoming patent cliffs.

Headquarters: Tokyo, Japan · Founded: 2005 · Employees: 14,099

Named competitors

Astellas Pharma at a glance

Size Astellas Pharma (4503.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $31.4B, the 50th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,725 on 18 Nov 2026.

Performance Over six months the shares gained 17.2%, against +8.2% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 18.6% over the last twelve months (peer median +16.4%); the operating margin is 23.4% (peer median 17.8%).

Valuation It trades at 12.9× forward earnings against a peer median of 22.9× (3rd cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -20 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 12.4 points above its cost of capital (5.4% WACC).

Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 20264503.T 118Peer median 108
Six months, rebased to 100: Astellas Pharma against the median of its 20 peers (local-currency closes).

Astellas Pharma financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥2.38T¥2.14T¥1.91T¥1.60T¥1.52T
Revenue growth—+12%+19%+6%—
Gross profit¥1.78T¥1.59T¥1.43T¥1.21T¥1.19T
EBITDA¥755B¥614B¥455B¥336B¥391B
Net income¥386B¥292B¥50.7B¥17.0B¥98.7B
Free cash flow¥497B¥509B¥165B¥143B¥296B
Capital expenditure¥111B¥84.6B¥57.3B¥82.5B¥88.5B
Total debt¥425B¥672B¥937B¥1.01T¥200B

Quarterly statements and history in the cockpit →

Astellas Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-10%0%+10%+20%4568DIVISLABZTSROIVBIIBINSM3692RPRXHLN4578INCYSDZVTRSSIG1276688235SUNPHARMAALNYGALD18014503.T6-month return →1-month return →
Up and to the right = strong over both horizons. Astellas Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×4568DIVISLABZTS3692RPRXHLNINCYSDZVTRSSIG688235SUNPHARMAALNYGALD18014503.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Astellas Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%4568DIVISLABZTSBIIB3692HLNINCYSIG688235SUNPHARMAALNYGALD18014503.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Astellas Pharma is the large dot.

Astellas Pharma competitors and peer comparison

Head to head with its named competitors (4503.T vs 4502.T vs 4568.T vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Astellas Pharma 4503.T$31.4B+17%+19%23%12.9×-9.0%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Daiichi Sankyo 4568.T$31.4B+8%+17%13%18.4×7.6%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Bayer BAYN.DE$60.3B+48%0%13%12.3×n/a

How Astellas Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Astellas Pharma against its 20 peers (data as of 18 Nov 2026)
Measure4503.TPeer medianRank in peer set
1-month return+12.4%+3.9%3rd highest of 21
6-month return+17.2%+8.2%9th highest of 21
Distance from 52-week high-1.6%-10.3%highest of 21
Revenue growth (TTM)+18.6%+16.4%10th highest of 21
Operating margin23.4%17.8%6th highest of 21
Forward P/E12.9×22.9×3rd cheapest of 19
Growth the price implies (Req g, 7 yrs)-9.0%10.5%least demanding of 19
Growth delivered (Del g)+11.4%+9.9%9th highest of 19
Hurdle (Req g minus delivered)-20.3 pp+2.9 pp3rd least demanding of 19
ROIC minus cost of capital+12.4 pp+4.8 pp8th highest of 21
EV / EBITDA6.9×22.4×cheapest of 18
Net debt / EBITDA0.2×-0.5×9th most indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Jiangsu Hengrui Pharmaceuticals 1276.HKHong Kong$44.9B-24%+11%27%28.1×9.1%+2.0%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%

Questions

Who are Astellas Pharma's main competitors?
Named competitors: Takeda (4502.T), Daiichi Sankyo (4568.T), Pfizer (PFE), Bayer (BAYN.DE). The cockpit's measured peer set (industry) also includes Daiichi Sankyo (4568.T), Divi's Laboratories (DIVISLAB.NS), Zoetis (ZTS), Roivant Sciences (ROIV), Biogen (BIIB), Insmed (INSM).
Is Astellas Pharma expensive compared with its peers?
On forward p/e it trades at 12.9× against a peer median of 22.9×, 3rd cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -20 pp: the price already allows for a slowdown.
How has Astellas Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +17.2% against +8.2% for the median peer; over one year +62.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.